Antibody therapies and their challenges in the treatment of age-related macular degeneration

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 95, Issue , 2015, Pages 158-172

  Volz, Cornelia ^a   Pauly, Diana ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Age related macular degeneration; Anti amyloid ; Anti angiogenic; Anti complement system; Anti inflammatory; Clinical studies; Intravitreal; Therapeutic antibody

Indexed keywords

ADALIMUMAB; AMYLOID BETA PROTEIN; BEVACIZUMAB; BLOOD CLOTTING FACTOR; COMPLEMENT; DACLIZUMAB; ECULIZUMAB; GSK 933776; INFLIXIMAB; LAMPALIZUMAB; LFG 316; MAB 1340; MONOCLONAL ANTIBODY; NM 9308; NM 9401; OMS 721; PF 04382923; RANIBIZUMAB; SONEPCIZUMAB; T 0A 106; TISSUE FACTOR ANTIBODY; UNCLASSIFIED DRUG; VOLOCIXIMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; ARTICLE; COMPLEMENT SYSTEM; GEOGRAPHIC ATROPHY; HUMAN; IMMUNOGLOBULIN STRUCTURE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; IMMUNOLOGY; MACULAR DEGENERATION; NEOVASCULARIZATION, PATHOLOGIC; PATHOPHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; COMPLEMENT SYSTEM PROTEINS; DRUG DESIGN; HUMANS; INFLAMMATION; MACULAR DEGENERATION; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84940906694     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.02.020     Document Type: Article

References (157)

1. J.W. Streilein Ocular immune privilege: therapeutic opportunities from an experiment of nature Nat. Rev. Immunol. 3 2003 879 889 10.1038/nri1224
2. Y.-C. Kim, B. Chiang, X. Wu, and M.R. Prausnitz Ocular delivery of macromolecules J. Control. Release 190 2014 172 181 10.1016/j.jconrel.2014.06.043
3. T.L. Jackson Human retinal molecular weight exclusion limit and estimate of species variation Invest. Ophthalmol. Vis. Sci. 44 2003 2141 2146 10.1167/iovs.02-1027
4. H. Kim, S.B. Robinson, and K.G. Csaky FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye Mol. Vis. 2009 2803 2812
5. J. Mordenti, R.A. Cuthbertson, N. Ferrara, K. Thomsen, L. Berleau, V. Licko, and et al. Toxicol. Pathol. 27 1999 536 544 < http://www.ncbi.nlm.nih.gov/pubmed/10528633 > (accessed 09.10.14)
6. D. Schweizer, T. Serno, and A. Goepferich Controlled release of therapeutic antibody formats Eur. J. Pharm. Biopharm. 88 2014 291 309
7. H.F. Edelhauser, C.L. Rowe-Rendleman, M.R. Robinson, D.G. Dawson, G.J. Chader, H.E. Grossniklaus, and et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications Invest. Ophthalmol. Vis. Sci. 51 2010 5403 5420 10.1167/iovs.10-5392
8. R.D. Jager, L.P. Aiello, S.C. Patel, and E.T. Cunningham Risks of intravitreous injection: a comprehensive review Retina 24 2004 676 698 10.1097/00006982-200410000-00002
9. A. Laude, L.E. Tan, C.G. Wilson, G. Lascaratos, M. Elashry, T. Aslam, and et al. Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics Prog. Retin. Eye Res. 29 2010 466 475 10.1016/j.preteyeres.2010.04.003
10. H. Nomoto, F. Shiraga, N. Kuno, E. Kimura, S. Fujii, K. Shinomiya, and et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits Invest. Ophthalmol. Vis. Sci. 50 2009 4807 4813 10.1167/iovs.08-3148
11. E. Behring, and S. Kitasato Über das Zustandekommen der Diphterie-Immunität und der Tetanus-Immunität bei Thieren Dtsch. Med. Wochenschr. 16 1890 1113 1114
12. P. Ehrlich Partial cell functions Nobel Lect. 1908 304 320 < http://www.nobelprize.org/nobel-prizes/medicine/laureates/1908/ehrlich-lecture.pdf >
13. S.L. Morrison, M.J. Johnson, L.A. Herzenberg, and V.T. Oi Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains Proc. Natl. Acad. Sci. U.S.A. 81 1984 6851 6855 < http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=392030&tool=pmcentrez&rendertype=abstract > (accessed 21.10.14)
14. G.L. Boulianne, N. Hozumi, and M.J. Shulman Production of functional chimaeric mouse/human antibody Nature 312 1984 643 646 < http://www.ncbi.nlm.nih.gov/pubmed/6095115 > (accessed 21.10.14)
15. C. Queen, W.P. Schneider, H.E. Selick, P.W. Payne, N.F. Landolfi, J.F. Duncan, and et al. A humanized antibody that binds to the interleukin 2 receptor Proc. Natl. Acad. Sci. U.S.A. 86 1989 10029 10033 < http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=298637&tool=pmcentrez&rendertype=abstract > (accessed 21.10.14)
16. F. Breitling, S. Dübel, T. Seehaus, I. Klewinghaus, and M. Little A surface expression vector for antibody screening Gene 104 1991 147 153 < http://www.ncbi.nlm.nih.gov/pubmed/1916287 > (accessed 21.10.14)
17. T. Clackson, H.R. Hoogenboom, A.D. Griffiths, and G. Winter Making antibody fragments using phage display libraries Nature 352 1991 624 628 10.1038/352624a0
18. C.F. Barbas, A.S. Kang, R.A. Lerner, and S.J. Benkovic Assembly of combinatorial antibody libraries on phage surfaces: the gene III site Proc. Natl. Acad. Sci. U.S.A. 88 1991 7978 7982 < http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=52428&tool=pmcentrez&rendertype=abstract > (accessed 14.10.14)
19. N. Lonberg, and D. Huszar Human antibodies from transgenic mice Int. Rev. Immunol. 13 1995 65 93 < http://www.ncbi.nlm.nih.gov/pubmed/7494109 > (accessed 21.10.14)
20. A. Jakobovits Production of fully human antibodies by transgenic mice Curr. Opin. Biotechnol. 6 1995 561 566 < http://www.ncbi.nlm.nih.gov/pubmed/7579668 > (accessed 21.10.14)
21. M. VanNewkirk The prevalence of age-related maculopathy: the visual impairment project Ophthalmology 107 2000 1593 1600 10.1016/S0161-6420(00)00175-5
22. F.L. Ferris, C.P. Wilkinson, A. Bird, U. Chakravarthy, E. Chew, K. Csaky, and et al. Clinical classification of age-related macular degeneration Ophthalmology 120 2013 844 851 10.1016/j.ophtha.2012.10.036
23. D. Ardeljan, and C.-C. Chan Aging is not a disease: distinguishing age-related macular degeneration from aging Prog. Retin. Eye Res. 37 2013 68 89 10.1016/j.preteyeres.2013.07.003
24. F. Jonasson, D.E. Fisher, G. Eiriksdottir, S. Sigurdsson, R. Klein, L.J. Launer, and et al. Five-year incidence, progression, and risk factors for age-related macular degeneration: the age, gene/environment susceptibility study Ophthalmology 121 2014 1766 1772 10.1016/j.ophtha.2014.03.013
25. H.M. Leibowitz, D.E. Krueger, L.R. Maunder, R.C. Milton, M.M. Kini, H.A. Kahn, and et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975 Surv. Ophthalmol. 24 1980 335 610 < http://www.ncbi.nlm.nih.gov/pubmed/7444756 > (accessed 29.10.14)
26. S.D. Solomon, K. Lindsley, S.S. Vedula, M.G. Krzystolik, and B.S. Hawkins Anti-vascular endothelial growth factor for neovascular age-related macular degeneration Cochrane Database Syst. Rev. 8 2014 CD005139 10.1002/14651858 CD005139.pub3
27. I. Bhutto, and G. Lutty Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex Mol. Aspects Med. 2012 1 23 10.1016/j.mam.2012.04.005
28. J. Ambati, J.P. Atkinson, and B.D. Gelfand Immunology of age-related macular degeneration Nat. Rev. Immunol. 13 2013 438 451 10.1038/nri3459
29. I. Bhutto, and G. Lutty Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex Mol. Aspects Med. 33 2012 295 317 10.1016/j.mam.2012.04.005
30. W.R. Green, and D.J. Wilson Choroidal neovascularization Ophthalmology 93 1986 1169 1176 < http://www.ncbi.nlm.nih.gov/pubmed/2433662 > (accessed 09.10.14)
31. O.A. Anderson, J.W.B. Bainbridge, and D.T. Shima Delivery of anti-angiogenic molecular therapies for retinal disease Drug Discov. Today 15 2010 272 282 10.1016/j.drudis.2010.02.004
32. H.E. Grossniklaus, and W.R. Green Choroidal neovascularization Am. J. Ophthalmol. 137 2004 496 503 10.1016/j.ajo.2003.09.042
33. E. Diaz-Rubio, E.A. Perez, and G. Giaccone Bevacizumab (Avastin) S. Duebel, Handb. Ther. Antibodies first ed. 2010 Wiley-VCH Weinheim, Germany 779 812
34. D.T. Shima, A.P. Adamis, N. Ferrara, K.T. Yeo, T.K. Yeo, R. Allende, and et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen Mol. Med. 1 1995 182 193 < http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2229943&tool=pmcentrez&rendertype=abstract > (accessed 09.10.14)
35. L.P. Aiello, J.M. Northrup, B.A. Keyt, H. Takagi, and M.A. Iwamoto Hypoxic regulation of vascular endothelial growth factor in retinal cells Arch. Ophthalmol. 113 1995 1538 1544 < http://www.ncbi.nlm.nih.gov/pubmed/7487623 > (accessed 09.10.14)
36. M.J. Tolentino, J.W. Miller, E.S. Gragoudas, F.A. Jakobiec, E. Flynn, K. Chatzistefanou, and et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate Ophthalmology 103 1996 1820 1828 < http://www.ncbi.nlm.nih.gov/pubmed/8942877 > (accessed 09.10.14)
37. N. Ferrara, K.J. Hillan, H.-P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat. Rev. Drug Discov. 3 2004 391 400 10.1038/nrd1381
38. M.J. Tolentino, D. Husain, P. Theodosiadis, E.S. Gragoudas, E. Connolly, J. Kahn, and et al. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization Arch. Ophthalmol. 118 2000 78 84 < http://www.ncbi.nlm.nih.gov/pubmed/10636419 > (accessed 25.09.14)
39. S. Michels, P.J. Rosenfeld, C.A. Puliafito, E.N. Marcus, and A.S. Venkatraman Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study Ophthalmology 112 2005 1035 1047 10.1016/j.ophtha.2005.02.007
40. A.A. Moshfeghi, P.J. Rosenfeld, C.A. Puliafito, S. Michels, E.N. Marcus, J.D. Lenchus, and et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study Ophthalmology 113 2006 2002 e1 e12 10.1016/j.ophtha.2006.05.070
41. P.J. Rosenfeld, A.A. Moshfeghi, and C.A. Puliafito Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration Ophthalmic Surg. Lasers Imag. 36 2005 331 335 < http://www.ncbi.nlm.nih.gov/pubmed/16156152 > (accessed 09.10.14)
42. Y.C. Kim, B. Chiang, X. Wu, and M.R. Prausnitz Ocular delivery of macromolecules J. Control. Release 190 2014 172 181 10.1016/j.jconrel.2014.06.043
43. L.G. Presta, H. Chen, S.J. O'Connor, V. Chisholm, Y.G. Meng, L. Krummen, and et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res. 57 1997 4593 4599 < http://www.ncbi.nlm.nih.gov/pubmed/9377574 > (accessed 05.10.14)
44. N. Papadopoulos, J. Martin, Q. Ruan, A. Rafique, M.P. Rosconi, E. Shi, and et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 2012 171 185 10.1007/s10456-011-9249-6
45. Y. Chen, C. Wiesmann, G. Fuh, B. Li, H.W. Christinger, P. McKay, and et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen J. Mol. Biol. 293 1999 865 881 10.1006/jmbi.1999.3192
46. N. Ferrara, L. Damico, N. Shams, H. Lowman, and R. Kim Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870 10.1097/01.iae.0000242842.14624.e7
47. J.S. Heier, A.N. Antoszyk, P.R. Pavan, S.R. Leff, P.J. Rosenfeld, T.A. Ciulla, and et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study Ophthalmology 113 633 2006 e1 e4 10.1016/j.ophtha.2005.10.052
48. S. Rofagha, R.B. Bhisitkul, D.S. Boyer, S.R. Sadda, and K. Zhang Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology 120 2013 2292 2299 10.1016/j.ophtha.2013.03.046
49. D.F. Martin, M.G. Maguire, S.L. Fine, G. Ying, G.J. Jaffe, J.E. Grunwald, and et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398 10.1016/j.ophtha.2012.03.053
50. L. Moja, E. Lucenteforte, K.H. Kwag, V. Bertele, A. Campomori, U. Chakravarthy, and et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration Cochrane Database Syst. Rev. 9 2014 CD011230 10.1002/14651858 CD011230.pub2
51. N. O'Brien, S.T. Jones, D.G. Williams, H.B. Cunningham, K. Moreno, B. Visentin, and et al. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies J. Lipid Res. 50 2009 2245 2257 10.1194/jlr.M900048-JLR200
52. J.M. Wojciak, N. Zhu, K.T. Schuerenberg, K. Moreno, W.S. Shestowsky, M. Hiraiwa, and et al. The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen Proc. Natl. Acad. Sci. U.S.A. 106 2009 17717 17722 10.1073/pnas.0906153106
53. S.E. Gardell, A.E. Dubin, and J. Chun Emerging medicinal roles for lysophospholipid signaling Trends Mol. Med. 12 2006 65 75 10.1016/j.molmed.2005.12.001
54. R. a Sabbadini Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration Br. J. Pharmacol. 162 2011 1225 1238 10.1111/j.1476-5381.2010.01118.x
55. S. Schwalm, J. Pfeilschifter, and A. Huwiler Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases Basic Clin. Pharmacol. Toxicol. 114 2014 44 49 10.1111/bcpt.12103
56. S. He, M.L. Jin, V. Worpel, and D.R. Hinton A role for connective tissue growth factor in the pathogenesis of choroidal neovascularization Arch. Ophthalmol. 121 2003 1283 1288 10.1001/archopht.121.9.1283
57. B. Xie, J. Shen, A. Dong, A. Rashid, G. Stoller, and P.A. Campochiaro Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization J. Cell. Physiol. 218 2009 192 198 10.1002/jcp.21588
58. Z.L. Lukowski, J. Min, A.R. Beattie, C.A. Meyers, M.A. Levine, G. Stoller, and et al. Prevention of ocular scarring after glaucoma filtering surgery using the monoclonal antibody LT1009 (Sonepcizumab) in a rabbit model J. Glaucoma 22 2013 145 151 10.1097/IJG.0b013e31822e8c83
59. L.J. Rao, J.M. Coney, J.P. Schartman, and L.J. Singerman Neovascular AMD: treatment beyond anti-VEGF Retin. Physician 12 2014 23 28
60. G. Atkinson, Lpath Completes Enrollment in its Phase 2 Clinical Trial of iSONEP for Wet Age-related Macular Degeneration, Press Release, 2014, pp. 1-3 (December).
61. V. Ramakrishnan, V. Bhaskar, D.A. Law, M.H.L. Wong, R.B. DuBridge, D. Breinberg, and et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent J. Exp. Ther. Oncol. 5 2006 273 286 < http://www.ncbi.nlm.nih.gov/pubmed/17024968 > (accessed 10.09.14)
62. T. Nakajima, M. Hirata, T.R. Shearer, and M. Azuma Mechanism for laser-induced neovascularization in rat choroid: accumulation of integrin α chain-positive cells and their ligands Mol. Vis. 20 2014 864 871 < http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4063356&tool=pmcentrez&rendertype=abstract >.
63. Z. Zhang, K. Vuori, J.C. Reed, and E. Ruoslahti The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression Proc. Natl. Acad. Sci. U.S.A. 92 1995 6161 6165 < http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=41662&tool=pmcentrez&rendertype=abstract > (accessed 09.10.14)
64. N. Umeda, S. Kachi, H. Akiyama, G. Zahn, D. Vossmeyer, R. Stragies, and et al. Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist Mol. Pharmacol. 69 2006 1820 1828 10.1124/mol.105.020941
65. Ophthotech Corporation, Ophthotech Form 10-Q Quarterly Report, NASDAQ Invest. Rep., 2013, pp. 1-64. < http://investors.ophthotech.com/secfiling.cfm?filingID=1104659-13-83939&CIK=1410939 >.
66. S.H. Lee Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2) Arch. Pharm. Res. 34 2011 1223 1226 10.1007/s12272-011-0821-9
67. J. Kim, T.E. Kim, J.-A. Kim, J.-H. Yun, S. Sohn, S.R. Shim, and et al. Intravitreal tanibirumab, a fully human monoclonal antibody against vascular endothelial growth factor receptor 2, partially suppresses and regresses laser-induced choroidal neovascularization in a rat model J. Ocul. Pharmacol. Ther. 2014 10.1089/jop.2014.0021
68. L. Wang, Z. Yang, Y. Yu, C. Cui, H. Guan, and H. Chen Blockage of tissue factor ameliorates the lesion of laser-induced choroidal neovascularization in mice Exp. Eye Res. 127 2014 117 123 10.1016/j.exer.2014.07.006
69. J.W. Crabb, M. Miyagi, X. Gu, K. Shadrach, K.A. West, H. Sakaguchi, and et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration Proc. Natl. Acad. Sci. U.S.A. 99 2002 14682 14687 10.1073/pnas.222551899
70. L.V. Johnson, W.P. Leitner, M.K. Staples, and D.H. Anderson Complement activation and inflammatory processes in Drusen formation and age related macular degeneration Exp. Eye Res. 73 2001 887 896 10.1006/exer.2001.1094
71. J.L. Haines, M.A. Hauser, S. Schmidt, W.K. Scott, L.M. Olson, P. Gallins, and et al. Complement factor H variant increases the risk of age-related macular degeneration Science 308 2005 419 421 10.1126/science.1110359
72. A.O. Edwards, R. Ritter, K.J. Abel, A. Manning, C. Panhuysen, and L.A. Farrer Complement factor H polymorphism and age-related macular degeneration Science 308 2005 421 424 10.1126/science.1110189
73. K.J. Katschke, P. Wu, R. Ganesan, R.F. Kelley, M. a Mathieu, P.E. Hass, and et al. Inhibiting alternative pathway complement activation by targeting the factor D exosite J. Biol. Chem. 287 2012 12886 12892 10.1074/jbc.M112.345082
74. M. Fung, P.G. Loubser, A. Undar, M. Mueller, C. Sun, W.N. Sun, and et al. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits J. Thorac. Cardiovasc. Surg. 122 2001 113 122 10.1067/mtc.2001.114777
75. J.E. Volanakis, S.R. Barnum, M. Giddens, and J.H. Galla Renal filtration and catabolism of complement protein D N. Engl. J. Med. 312 1985 395 399 10.1056/NEJM198502143120702
76. P.H. Lesavre, and H.J. Müller-Eberhard Mechanism of action of factor D of the alternative complement pathway J. Exp. Med. 148 1978 1498 1509 < http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2185104&tool=pmcentrez&rendertype=abstract > (accessed 22.09.14)
77. H.P.N. Scholl, P. Charbel Issa, M. Walier, S. Janzer, B. Pollok-Kopp, F. Börncke, and et al. Systemic complement activation in age-related macular degeneration PLoS ONE 3 2008 e2593 10.1371/journal.pone.0002593
78. C.M. Stanton, J.R.W. Yates, A.I. den Hollander, J.M. Seddon, A. Swaroop, D. Stambolian, and et al. Complement factor D in age-related macular degeneration Invest. Ophthalmol. Vis. Sci. 52 2011 8828 8834 10.1167/iovs.11-7933
79. B. Rohrer, Y. Guo, K. Kunchithapautham, and G.S. Gilkeson Eliminating complement factor D reduces photoreceptor susceptibility to light-induced damage Invest. Ophthalmol. Vis. Sci. 48 2007 5282 5289 10.1167/iovs.07-0282
80. K.M. Loyet, J. Good, T. Davancaze, L. Sturgeon, X. Wang, J. Yang, and et al. Complement inhibition in cynomolgus monkey by anti-factor D antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration J. Pharmacol. Exp. Ther. 2014 10.1124/jpet.114.215921
81. D. V Do, D.J. Pieramici, M. van Lookeren Campagne, T. Beres, M. Friesenhahn, Y. Zhang, and et al. A phase ia dose-escalation study of the anti-factor D monoclonal antibody fragment FCFD4514S in patients with geographic atrophy Retina 34 2014 313 320 10.1097/IAE.0b013e3182979ddd
82. F.G. Holz, The MAHALO Phase II study: safety, tolerability and evidence of activity of lampalizumab (anti-factor D) in patients with geographic atrophy (GA) secondary to age-related Macular degeneration (AMD), in: Euretina Meet., September, 2013, p. 28.
83. Roche Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA) Invest. Updat. 2014 1 < http://www.roche.com/investors/ir-update/inv-update-2014-09-15.htm >
84. M. Kaplan Eculizumab (Alexion) Curr. Opin. Invest. Drugs 3 2002 1017 1023 < http://www.ncbi.nlm.nih.gov/pubmed/12186261 > (accessed 29.10.14)
85. Alexion, Soliris (Eculizumab) Package Insert, 2014.
86. Y. Frei, J.D. Lambris, and B. Stockinger Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies Mol. Cell. Probes 1 1987 141 149 < http://www.ncbi.nlm.nih.gov/pubmed/3453897 > (accessed 16.09.14)
87. J. Liu, D.A. Copland, S. Horie, B.P. Morgan, L.B. Nicholson, A.D. Dick, Local anti-C5 therapy suppresses experimental choroidal neovascularization through reduction of macrophage infiltrate, in: ARVO Annu. Meet. Abstr., 2012, p. 1236.
88. H.F. Langer, K.-J. Chung, V. V Orlova, E.Y. Choi, S. Kaul, M.J. Kruhlak, and et al. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis Blood 116 2010 4395 4403 10.1182/blood-2010-01-261503
89. Z. Yehoshua, C.A. de Amorim Garcia Filho, R.P. Nunes, G. Gregori, F.M. Penha, A. a Moshfeghi, and et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study Ophthalmology 121 2014 693 701 10.1016/j.ophtha.2013.09.044
90. C.A.deA. Garcia Filho, Z. Yehoshua, G. Gregori, R.P. Nunes, F.M. Penha, A.A. Moshfeghi, and et al. Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration Ophthalmic Surg. Lasers Imag. Retina 45 2014 18 31 10.3928/23258160-20131217-01
91. A. Carrion, B. Etemad-Gilbertson, J. Zhou, A. Soni, M. Roguska, Characterization of the stoichiometry of human complement C5 binding LFG316, in: ARVO Meet. Abstr., 2014, Program Number 3432.
92. M. Roguska, I. Splawski, B. Diefenbach-Streiber, E. Dolan, B. Etemad-Gilbertson, J.-M. Rondeau, et al., Generation and characterization of LFG316, a fully-human anti-C5 antibody for the treatment of age-related macular degeneration, in: ARVO Meet. Abstr., 2014, Programm Number 3433.
93. H.-W. Schwaeble, T.A. Dudler, C.E. Tedford, J.B. Parent, G.A. Demopulos, Methods for Treating Disseminated Intravascular Coagulation by Inhibiting masp-2 dependent Complement Activation, WO2011047346A1, 2011.
94. W.J. Schwaeble, N.J. Lynch, J.E. Clark, M. Marber, N.J. Samani, Y.M. Ali, and et al. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury Proc. Natl. Acad. Sci. U.S.A. 108 2011 7523 7528 10.1073/pnas.1101748108
95. K.M. Loyet, L.E. Deforge, K.J. Katschke, L. Diehl, R.R. Graham, L. Pao, and et al. Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration Invest. Ophthalmol. Vis. Sci. 53 2012 6628 6637 10.1167/iovs.12-9587
96. D. Ricklin, and J.D. Lambris Complement in immune and inflammatory disorders: therapeutic interventions J. Immunol. 190 2013 3839 3847 10.4049/jimmunol.1203200
97. J.M. Thurman, D.M. Kraus, G. Girardi, D. Hourcade, H.J. Kang, P.A. Royer, and et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice Mol. Immunol. 42 2005 87 97 10.1016/j.molimm.2004.07.043
98. R. Bansal, Method of Inhibiting Complement Activation with Factor Bb Specific Antibodies, WO2009/029669A1, 2009.
99. J. Hunter, D.L. Sheridan, Humaneered Anti-factor B Antibody, WO2013/177035A2, 2013.
100. I. Leinhase, M. Rozanski, D. Harhausen, J.M. Thurman, O.I. Schmidt, A.M. Hossini, and et al. Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice J. Neuroinflamm. 4 2007 13 10.1186/1742-2094-4-13
101. X. Hu, V.M. Holers, J.M. Thurman, T.R. Schoeb, T.N. Ramos, and S.R. Barnum Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE Mol. Immunol. 54 2013 302 308 10.1016/j.molimm.2012.12.018
102. C. Kemper, J.P. Atkinson, and D.E. Hourcade Properdin: emerging roles of a pattern-recognition molecule Annu. Rev. Immunol. 28 2010 131 155 10.1146/annurev-immunol-030409-101250
103. R. Gupta-Bansal, J.B. Parent, and K.R. Brunden Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies Mol. Immunol. 37 2000 191 201 < http://www.ncbi.nlm.nih.gov/pubmed/10930626 > (accessed 09.10.14)
104. D. Pauly, B.M. Nagel, J. Reinders, T. Killian, M. Wulf, S. Ackermann, and et al. A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples PLoS ONE 9 2014 e96371 10.1371/journal.pone.0096371
105. T. Miwa, S. Sato, D. Gullipalli, M. Nangaku, and W.-C. Song Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice J. Immunol. 190 2013 3552 3559 10.4049/jimmunol.1202275
106. J. Miao, A.M. Lesher, T. Miwa, S. Sato, D. Gullipalli, and W.-C. Song Tissue-specific deletion of Crry from mouse proximal tubular epithelial cells increases susceptibility to renal ischemia-reperfusion injury Kidney Int. 86 2014 726 737 10.1038/ki.2014.103
107. M.R. Daha Unexpected role for properdin in complement C3 glomerulopathies J. Am. Soc. Nephrol. 24 2013 5 7 10.1681/ASN.2012111110
108. W. Ma, L. Zhao, and W.T. Wong Microglia in the outer retina and their relevance to pathogenesis of age-related macular degeneration Adv. Exp. Med. Biol. 723 2012 37 42 10.1007/978-1-4614-0631-0-6
109. J.G. Hollyfield, V.L. Bonilha, M.E. Rayborn, X. Yang, K.G. Shadrach, L. Lu, and et al. Oxidative damage-induced inflammation initiates age-related macular degeneration Nat. Med. 14 2008 194 198 10.1038/nm1709
110. B. Liu, L. Wei, C. Meyerle, J. Tuo, H.N. Sen, Z. Li, and et al. Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration J. Transl. Med. 9 2011 1 12 10.1186/1479-5876-9-111
111. S. Camelo Potential sources and roles of adaptive immunity in age-related macular degeneration: shall we rename AMD into autoimmune macular disease? Autoimmune Dis. 2014 2014 532487 10.1155/2014/532487
112. C.P. Shah, and J.S. Heier The future of neovascular age-related macular degeneration A.C. Ho, C.D. Regillo, Age-related Macular Degener. Diagnosis Treat. 2011 Springer New York New York, NY 135 153 10.1007/978-1-4614-0125-4
113. P.A. Petrou, K. Shimel, C.A. Cukras, L.F. Ferris, E.Y. Chew, W.T. Wong, Intravitreal sirolimus for the treatment of bilateral geographic atrophy associated with age-related macular degeneration: results of a phase I/II trial, in: ARVO Annu. Meet. Abstr., 2014, p. 5892.
114. M. Fràter-Schröder, W. Risau, R. Hallmann, P. Gautschi, and P. Böhlen Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo Proc. Natl. Acad. Sci. U.S.A. 84 1987 5277 5281 < http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=298838&tool=pmcentrez&rendertype=abstract > (accessed 09.10.14)
115. P. Lichtlen, T.T. Lam, T.M. Nork, T. Streit, and D.M. Urech Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105 Invest. Ophthalmol. Vis. Sci. 51 2010 4738 4745 10.1167/iovs.09-4890
116. R.P.A. Manzano, G.A. Peyman, P.E. Carvounis, F.M. Damico, R.G. Aguiar, G.L. Ioshimoto, and et al. Toxicity of high-dose intravitreal adalimumab (Humira) in the rabbit J. Ocul. Pharmacol. Ther. 27 2011 327 331 10.1089/jop.2010.0174
117. A.C. Myers, F. Ghosh, S. Andréasson, and V. Ponjavic Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab Curr. Eye Res. 2014 1 11 10.3109/02713683.2014.898309
118. L. Wu, J.F. Arevalo, E. Hernandez-Bogantes, C.V. Regatieri, J.A. Roca, and M.E. Farah Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group J. Ocul. Pharmacol. Ther. 29 2013 366 371 10.1089/jop.2012.0203
119. S. Androudi, E. Tsironi, C. Kalogeropoulos, A. Theodoridou, and P. Brazitikos Intravitreal adalimumab for refractory uveitis-related macular edema Ophthalmology 117 2010 1612 1616 10.1016/j.ophtha.2009.12.011
120. M. Wiekowski, and C. Antoni Infliximab (Remicade) S. Duebel, Handb. Ther. Antibodies2 first ed. 2010 Wiley-VCH Weinheim, Germany 885 904
121. F. Atzeni, P. Sarzi-Puttini, A. Doria, L. Iaccarino, and F. Capsoni Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review Autoimmun. Rev. 4 2005 144 152 10.1016/j.autrev.2004.08.004
122. S.A. Siegel, D.J. Shealy, M.T. Nakada, J. Le, D.S. Woulfe, L. Probert, and et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo Cytokine 7 1995 15 25 10.1006/cyto.1995.1003
123. X. Shi, I. Semkova, P.S. Müther, S. Dell, N. Kociok, and A.M. Joussen Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization Exp. Eye Res. 83 2006 1325 1334 10.1016/j.exer.2006.07.007
124. J.L. Olson, R.J. Courtney, and N. Mandava Intravitreal infliximab and choroidal neovascularization in an animal model Arch. Ophthalmol. 125 2007 1221 1224 10.1001/archopht.125.9.1221
125. P.G. Theodossiadis, V.S. Liarakos, P.P. Sfikakis, I.A. Vergados, and G.P. Theodossiadis Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration Am. J. Ophthalmol. 147 2009 825 830 10.1016/j.ajo.2008.12.004
126. M. Giganti, P.M. Beer, N. Lemanski, C. Hartman, J. Schartman, and N. Falk Adverse events after intravitreal infliximab (Remicade) Retina 30 2010 71 80 10.1097/IAE.0b013e3181bcef3b
127. L. Arias, J.M. Caminal, M.B. Badia, M.J. Rubio, J. Catala, and O. Pujol Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy Retina 30 2010 1601 1608 10.1097/IAE.0b013e3181e9f942
128. F. Semeraro, M.R. Romano, P. Danzi, M. Angi, and C. Costagliola Intravitreal infliximab for choroidal neovascularization in patients refractory to conventional treatments Int. J. Immunopathol. Pharmacol. 26 2013 765 768 < http://www.ncbi.nlm.nih.gov/pubmed/24067474 > (accessed 09.10.14)
129. L.G.A. de Freitas, D.L.C. Isaac, W.T. Tannure, L.A.R. Gabriel, R.G. dos Reis, A.R. Rassi, and et al. Intravitreal bevacizumab combined with infliximab in the treatment of choroidal neovascularization secondary to age-related macular degeneration: case report series Arq. Bras. Oftalmol. 76 2013 180 184 < http://www.ncbi.nlm.nih.gov/pubmed/23929080 > (accessed 09.10.14)
130. R.B. Nussenblatt, G. Byrnes, H.N. Sen, S. Yeh, L. Faia, C. Meyerle, and et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization Retina 30 2011 1579 1587 10.1097/IAE.0b013e3181e7978e
131. P.M. van Hagen, G.S. Baarsma, C.E. van Bilsen, R.W. Kuijpers, J.A. van Laar, M. van der Ent, and et al. A noncontrolled trial of anti-TNF-α chimeric monoclonal antibody (infliximab, Remicade(®)) in exudative age-related macular degeneration Acta Ophthalmol. 2014 1 2 10.1111/aos.12471
132. T.A. Waldmann Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey J. Clin. Immunol. 27 2007 1 18 10.1007/s10875-006-9060-0
133. C.I. Carswell, G.L. Plosker, and A.J. Wagstaff Daclizumab: a review of its use in the management of organ transplantation BioDrugs 15 2001 745 773 < http://www.ncbi.nlm.nih.gov/pubmed/11707149 > (accessed 09.10.14)
134. B. Bielekova, M. Catalfamo, S. Reichert-Scrivner, A. Packer, M. Cerna, T.A. Waldmann, and et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis Proc. Natl. Acad. Sci. U.S.A. 103 2006 5941 5946 10.1073/pnas.0601335103
135. J. Goebel, E. Stevens, K. Forrest, and T.L. Roszman Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events Transpl. Immunol. 8 2000 153 159 < http://www.ncbi.nlm.nih.gov/pubmed/11147695 > (accessed 09.10.14)
136. B. IDEC, AbbVie, Positive Top-line Results in Phase III Daclizumab High-Yield Process Study in MS, MS-UK, 2014, p. 1. < http://www.ms-uk.org/zenapax >.
137. D.H. Anderson, K.C. Talaga, A.J. Rivest, E. Barron, G.S. Hageman, and L. V Johnson Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration Exp. Eye Res. 78 2004 243 256 < http://www.ncbi.nlm.nih.gov/pubmed/14729357 > (accessed 09.10.14)
138. T. Dentchev, A.H. Milam, V.M.-Y. Lee, J.Q. Trojanowski, and J.L. Dunaief Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas Mol. Vis. 9 2003 184 190 < http://www.ncbi.nlm.nih.gov/pubmed/12764254 > (accessed 09.10.14)
139. J.M. Nussbaum, M.E. Seward, and G.S. Bloom Alzheimer disease: a tale of two prions Prion 7 2013 14 19 10.4161/pri.22118
140. T. Yoshida, K. Ohno-Matsui, S. Ichinose, T. Sato, N. Iwata, T.C. Saido, and et al. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration J. Clin. Invest. 115 2005 2793 2800 10.1172/JCI24635
141. L.V. Johnson, W.P. Leitner, A.J. Rivest, M.K. Staples, M.J. Radeke, and D.H. Anderson The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration Proc. Natl. Acad. Sci. U.S.A. 99 2002 11830 11835 10.1073/pnas.192203399
142. J.-D. Ding, J. Lin, B.E. Mace, R. Herrmann, P. Sullivan, and C. Bowes Rickman Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model Vision. Res. 48 2008 339 345 10.1016/j.visres.2007.07.025
143. B.B. Berger, P.D. Garzone, I. Gunderson, P.M. Fanning, G. Wong, K.H. Liao, et al., Phase I, Masked, Placebo - controlled, single and multiple ascending intravenous dose studies evaluating systemic and ocular safety, tolerability, and visual acuity effects of RN6G (PF - 04382923) in subjects with dry, age-related macular degeneration, in: ARVO Annu. Meet. Abstr., 2013, p. 4505.
144. J.-D. Ding, L. V Johnson, R. Herrmann, S. Farsiu, S.G. Smith, M. Groelle, and et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration Proc. Natl. Acad. Sci. U.S.A 108 2011 E279 E287 10.1073/pnas.1100901108
145. J.R. Heyen, J. Rojko, M. Evans, T.P. Brown, W.F. Bobrowski, A. Vitsky, and et al. Characterization, biomarkers, and reversibility of a monoclonal antibody-induced immune complex disease in cynomolgus monkeys (Macaca fascicularis) Toxicol. Pathol. 42 2014 765 773 10.1177/0192623314522559
146. 2 antibody for treatment of age-related retinal degenerative diseases, in: 4th Int. Conf. Clin. Exp. Ophthalmol., Baltimore, 2014.
147. GlaxoSmithKline, GlaxoSmithkline Study Register, Study Regist., 2014. < http://www.gsk-clinicalstudyregister.com/compounds/gsk933776#ps >.
148. A. Klettner, N. Tahmaz, M. Dithmer, E. Richert, and J. Roider Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis Br. J. Ophthalmol. 98 2014 1448 1452 10.1136/bjophthalmol-2014-305105
149. K.M. Bell-McGuinn, C.M. Matthews, S.N. Ho, M. Barve, L. Gilbert, R.T. Penson, and et al. A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer Gynecol. Oncol. 121 2011 273 279 10.1016/j.ygyno.2010.12.362
150. B. Besse, L.C. Tsao, D.T. Chao, Y. Fang, J.-C. Soria, S. Almokadem, and et al. Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer Ann. Oncol. 24 2013 90 96 10.1093/annonc/mds281
151. R. Milner, S.J. Crocker, S. Hung, X. Wang, R.F. Frausto, and G.J. del Zoppo Fibronectin- and vitronectin-induced microglial activation and matrix metalloproteinase-9 expression is mediated by integrins alpha5beta1 and alphavbeta5 J. Immunol. 178 2007 8158 8167 < http://www.ncbi.nlm.nih.gov/pubmed/17548654 > (accessed 09.10.14)
152. H. Kim, M. Ahn, S. Choi, M. Kim, K.-B. Sim, J. Kim, and et al. Potential role of fibronectin in microglia/macrophage activation following cryoinjury in the rat brain: an immunohistochemical study Brain Res. 1502 2013 11 19 10.1016/j.brainres.2013.01.043
153. M.R. Kozlowski RPE cell senescence. A key contributor to age-related macular degeneration Med. Hypotheses 78 2012 505 510 10.1016/j.mehy.2012.01.018
154. R.R. Priya, E.Y. Chew, and A. Swaroop Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management Ophthalmology 119 2012 2526 2536 10.1016/j.ophtha.2012.06.042
155. M. El Sanharawi, L. Kowalczuk, E. Touchard, S. Omri, Y. de Kozak, and F. Behar-Cohen Protein delivery for retinal diseases: from basic considerations to clinical applications Prog. Retin. Eye Res. 29 2010 443 465 10.1016/j.preteyeres.2010.04.001
156. Y. Saishin, Y. Saishin, K. Takahashi, R. Lima e Silva, D. Hylton, J.S. Rudge, and et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier J. Cell. Physiol. 195 2003 241 248 10.1002/jcp.10246
157. R.L. Avery What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br. J. Ophthalmol. 98 Suppl. 1 2014 i7 i10 10.1136/bjophthalmol-2013-303844